BRPI0809685A2 - compostos, composição farmaceuticamente aceitável e métodos de inibição da replicação do vírus da hepatite c e de tratamento ou prevenção da infecção do vírus da hepatite c em mamífero necessitado do mesmo - Google Patents

compostos, composição farmaceuticamente aceitável e métodos de inibição da replicação do vírus da hepatite c e de tratamento ou prevenção da infecção do vírus da hepatite c em mamífero necessitado do mesmo

Info

Publication number: BRPI0809685A2
Authority: BR; Brazil
Prior art keywords: hepatitis; mammal; treating; methods; pharmaceutically acceptable
Prior art date: 2007-04-03

Application number

BRPI0809685A

Other languages

English (en)

Inventor

Chinh Viet Tran

David Kucera

Douglas Eric Murphy

Frank Ruebsam

Fritz Blatter

Lijiang Chen

Martin Viertelhaus

Peter S Dragovich

Yuefen Zhou

Original Assignee

Anadys Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-03

Filing date

2008-04-02

Publication date

2016-09-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0809685(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-04-02 Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc

2016-09-27 Publication of BRPI0809685A2 publication Critical patent/BRPI0809685A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Materials For Medical Uses (AREA)

BRPI0809685A 2007-04-03 2008-04-02 compostos, composição farmaceuticamente aceitável e métodos de inibição da replicação do vírus da hepatite c e de tratamento ou prevenção da infecção do vírus da hepatite c em mamífero necessitado do mesmo BRPI0809685A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US90747807P	2007-04-03	2007-04-03
PCT/US2008/059164 WO2008124450A1 (en)	2007-04-03	2008-04-02	5,6-dihydro-1h-pyridin-2-one compounds

Publications (1)

Publication Number	Publication Date
BRPI0809685A2 true BRPI0809685A2 (pt)	2016-09-27

Family

ID=39831340

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0809685A BRPI0809685A2 (pt)	2007-04-03	2008-04-02	compostos, composição farmaceuticamente aceitável e métodos de inibição da replicação do vírus da hepatite c e de tratamento ou prevenção da infecção do vírus da hepatite c em mamífero necessitado do mesmo

Country Status (22)

Country	Link
US (6)	US7939524B2 (pt)
EP (1)	EP2129224B1 (pt)
JP (2)	JP5739662B2 (pt)
KR (1)	KR101542516B1 (pt)
CN (2)	CN101677563B (pt)
AR (1)	AR065927A1 (pt)
AU (1)	AU2008237364B2 (pt)
BR (1)	BRPI0809685A2 (pt)
CA (1)	CA2682584C (pt)
CL (1)	CL2008000959A1 (pt)
EA (1)	EA017685B1 (pt)
ES (1)	ES2578302T3 (pt)
IL (2)	IL201312A (pt)
MX (1)	MX2009010564A (pt)
MY (1)	MY157961A (pt)
NZ (1)	NZ580445A (pt)
PE (1)	PE20090220A1 (pt)
TN (1)	TN2009000398A1 (pt)
TW (2)	TWI427079B (pt)
UA (1)	UA100120C2 (pt)
WO (1)	WO2008124450A1 (pt)
ZA (1)	ZA200907673B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102584649A (zh)	2006-06-22	2012-07-18	安那迪斯药品股份有限公司	吡咯并[1,2-b]哒嗪酮化合物
UA100120C2 (en)	2007-04-03	2012-11-26	Анадис Фармасьютикалз, Инк.	5,6-dihydro-1h-pyridin-2-one compounds
CN102316871B (zh) *	2008-06-10	2014-06-04	安那迪斯药品股份有限公司	[1，2，4]噻二嗪1，1-二氧化合物
WO2010042834A1 (en)	2008-10-09	2010-04-15	Anadys Pharmaceuticals, Inc.	A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
TW201026675A (en) *	2008-10-09	2010-07-16	Anadys Pharmaceuticals Inc	5,6-dihydro-1H-pyridin-2-one compounds
BR112012009796A2 (pt)	2009-10-28	2020-08-18	Anadys Pharmaceuticals, Inc.	composto, métodos para tratar ou prevenir infecções por vírus da hepatite c em mamífero necessitado destes usos de composto e de composição farmacêutica.
BR112012014729A2 (pt)	2009-12-18	2016-03-29	Boehringer Ingelheim Int	terapia combinada contra hcv
WO2012158271A1 (en)	2011-04-06	2012-11-22	Anadys Pharmaceuticals, Inc.	Bridged polycyclic compounds as antiviral agents
US8815847B2 (en)	2011-06-07	2014-08-26	Anadys Pharmaceuticals, Inc.	[1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid
TW201402133A (zh) *	2012-06-12	2014-01-16	Hoffmann La Roche	組合治療性組成物
US8816120B2 (en)	2013-01-14	2014-08-26	Hoffmann-La Roche Inc.	Process for the preparation of N-(4-nitro-2-sulfamoyl-phenyl)-malonamic acid methyl ester and N-(4-amino-2-sulfamoyl-phenyl)-malonamic acid methyl ester
SI3421468T1 (sl) *	2013-11-13	2021-03-31	Vertex Pharmaceuticals Incorporated	Postopki za pripravo inhibitorjev replikacije virusov influence
WO2016130043A1 (ru) *	2015-02-13	2016-08-18	Александ Васильевич ИВАЩЕНКО	Бензо[1,2,4]тиадиазиновые ингибиторы репликации вируса гепатита в и фармацевтическая композиция для лечения гепатита в
PE20190622A1 (es)	2016-06-02	2019-04-26	Abbvie Inc	Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
HUE054428T2 (hu)	2017-12-01	2021-09-28	Abbvie Inc	Glükokortikoid receptor agonista és annak immunkonjugátumai
WO2020223255A1 (en)	2019-04-29	2020-11-05	Solent Therapeutics, Llc	3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2
CN113292574B (zh) *	2020-02-21	2022-05-03	四川大学	一类手性多环的托品烷化合物及其制备方法和用途
US12274700B1 (en)	2020-10-30	2025-04-15	Accencio LLC	Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
JP7435515B2 (ja) *	2021-03-17	2024-02-21	株式会社村田製作所	部品収容装置

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4171361A (en) *	1977-03-31	1979-10-16	Eli Lilly And Company	1-Substituted-3-amino-6,7-dialkoxy-1H-1,2,4-benzothiadiazine-1-oxides
US4889851A (en) *	1986-11-21	1989-12-26	Fujisawa Pharmaceutical Co, Ltd.	Benzothiadiazine compounds, and pharmaceutical composition comprising the same
EP1292310A1 (en)	2000-05-10	2003-03-19	SmithKline Beecham Corporation	Novel anti-infectives
AR036081A1 (es)	2001-06-07	2004-08-11	Smithkline Beecham Corp	Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
AU2002365198A1 (en)	2001-10-30	2003-07-30	Smithkline Beecham Corporation	Novel anti-infectives
US20050075331A1 (en) *	2003-10-06	2005-04-07	Pratt John K.	Anti-infective agents
ATE493408T1 (de) *	2002-11-01	2011-01-15	Abbott Lab	Antiinfektiöse mittel
BR0315897A (pt)	2002-11-01	2008-05-13	Abbott Lab	agentes antiinfecciosos
US7601709B2 (en) *	2003-02-07	2009-10-13	Enanta Pharmaceuticals, Inc.	Macrocyclic hepatitis C serine protease inhibitors
CA2561305C (en) *	2004-03-24	2013-07-30	Bharat Lagu	Tetrahydro-indazole cannabinoid modulators
US7439246B2 (en) *	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
SG137868A1 (en) *	2004-08-23	2007-12-28	Hoffmann La Roche	Heterocyclic antiviral compounds
GT200500373A (es) *	2004-12-17	2006-10-02		Compuestos de piridazinones
WO2006093801A1 (en) *	2005-02-25	2006-09-08	Abbott Laboratories	Thiadiazine derivatives useful as anti-infective agents
AU2006240730A1 (en)	2005-04-21	2006-11-02	Nippon Shinyaku Co., Ltd.	Phthalazinone derivative and pharmaceutical comprising the same
BRPI0611388A2 (pt) *	2005-05-04	2010-09-08	Hoffmann La Roche	compostos antivirais heterocìclicos, uso dos mesmos e composição farmacêutica
WO2008051637A2 (en)	2006-06-22	2008-05-02	Anadys Pharmaceuticals, Inc.	Pyridazinone compounds
CN102584649A (zh) *	2006-06-22	2012-07-18	安那迪斯药品股份有限公司	吡咯并[1,2-b]哒嗪酮化合物
TW200840572A (en)	2006-12-12	2008-10-16	Anadys Pharmaceuticals Inc	5,6-dihydro-1H-pyridin-2-one compounds
US20080214529A1 (en)	2006-12-12	2008-09-04	Frank Ruebsam	SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS
US20080188466A1 (en)	2006-12-21	2008-08-07	Anadys Pharmaceuticals, Inc.	Pyridazinone compounds
US20080275032A1 (en)	2006-12-29	2008-11-06	Yuefen Zhou	Pyridazinone compounds
US20080227774A1 (en)	2007-03-15	2008-09-18	Frank Ruebsam	5,5-disubstituted-indolizinone compounds
UA100120C2 (en)	2007-04-03	2012-11-26	Анадис Фармасьютикалз, Инк.	5,6-dihydro-1h-pyridin-2-one compounds
US7834009B2 (en) *	2007-08-27	2010-11-16	Anadys Pharmaceuticals, Inc.	4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds

2008
- 2008-02-04 UA UAA200910844A patent/UA100120C2/ru unknown
- 2008-04-02 MY MYPI20094109A patent/MY157961A/en unknown
- 2008-04-02 NZ NZ580445A patent/NZ580445A/en not_active IP Right Cessation
- 2008-04-02 MX MX2009010564A patent/MX2009010564A/es active IP Right Grant
- 2008-04-02 AU AU2008237364A patent/AU2008237364B2/en not_active Ceased
- 2008-04-02 CL CL2008000959A patent/CL2008000959A1/es unknown
- 2008-04-02 EP EP08733076.7A patent/EP2129224B1/en active Active
- 2008-04-02 WO PCT/US2008/059164 patent/WO2008124450A1/en not_active Ceased
- 2008-04-02 KR KR1020097023036A patent/KR101542516B1/ko not_active Expired - Fee Related
- 2008-04-02 CN CN200880018225.2A patent/CN101677563B/zh not_active Expired - Fee Related
- 2008-04-02 JP JP2010502271A patent/JP5739662B2/ja not_active Expired - Fee Related
- 2008-04-02 EA EA200970916A patent/EA017685B1/ru unknown
- 2008-04-02 ES ES08733076.7T patent/ES2578302T3/es active Active
- 2008-04-02 PE PE2008000597A patent/PE20090220A1/es active IP Right Grant
- 2008-04-02 CA CA2682584A patent/CA2682584C/en active Active
- 2008-04-02 BR BRPI0809685A patent/BRPI0809685A2/pt not_active Application Discontinuation
- 2008-04-02 TW TW097111924A patent/TWI427079B/zh not_active IP Right Cessation
- 2008-04-02 CN CN201410217806.6A patent/CN104086540B/zh not_active Expired - Fee Related
- 2008-04-02 US US12/061,499 patent/US7939524B2/en active Active
- 2008-04-02 TW TW103101356A patent/TWI481588B/zh not_active IP Right Cessation
- 2008-04-03 AR ARP080101383A patent/AR065927A1/es active IP Right Grant
2009
- 2009-09-30 TN TNP2009000398A patent/TN2009000398A1/fr unknown
- 2009-10-01 IL IL201312A patent/IL201312A/en active IP Right Grant
- 2009-11-02 ZA ZA2009/07673A patent/ZA200907673B/en unknown
2011
- 2011-03-08 US US13/043,167 patent/US8101800B2/en not_active Expired - Fee Related
2012
- 2012-01-23 US US13/356,063 patent/US8236948B2/en not_active Expired - Fee Related
- 2012-08-06 US US13/567,667 patent/US8546602B2/en not_active Expired - Fee Related
2013
- 2013-04-11 IL IL225694A patent/IL225694A/en active IP Right Grant
- 2013-09-30 US US14/041,376 patent/US8765741B2/en active Active
2014
- 2014-06-10 US US14/300,306 patent/US9156832B2/en not_active Expired - Fee Related
2015
- 2015-02-16 JP JP2015027744A patent/JP5934403B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP5739662B2 (ja)	2015-06-24
IL201312A (en)	2015-05-31
EA200970916A1 (ru)	2010-04-30
US20140031346A1 (en)	2014-01-30
JP2015134783A (ja)	2015-07-27
ZA200907673B (en)	2014-04-30
US8236948B2 (en)	2012-08-07
US9156832B2 (en)	2015-10-13
KR20090127437A (ko)	2009-12-11
EA017685B1 (ru)	2013-02-28
MY157961A (en)	2016-08-30
TWI481588B (zh)	2015-04-21
US8765741B2 (en)	2014-07-01
AU2008237364B2 (en)	2014-03-06
CA2682584C (en)	2017-03-14
CN101677563A (zh)	2010-03-24
WO2008124450A1 (en)	2008-10-16
US7939524B2 (en)	2011-05-10
US20100034773A1 (en)	2010-02-11
CL2008000959A1 (es)	2008-11-03
ES2578302T3 (es)	2016-07-22
HK1201822A1 (en)	2015-09-11
CN104086540B (zh)	2017-04-12
JP5934403B2 (ja)	2016-06-15
US20150065492A1 (en)	2015-03-05
US8101800B2 (en)	2012-01-24
EP2129224A4 (en)	2011-01-05
AR065927A1 (es)	2009-07-08
CN104086540A (zh)	2014-10-08
CN101677563B (zh)	2014-06-25
MX2009010564A (es)	2009-10-26
PE20090220A1 (es)	2009-03-12
NZ580445A (en)	2012-01-12
TN2009000398A1 (en)	2010-12-31
UA100120C2 (en)	2012-11-26
IL201312A0 (en)	2010-05-31
JP2010523586A (ja)	2010-07-15
KR101542516B1 (ko)	2015-08-06
EP2129224A1 (en)	2009-12-09
HK1137119A1 (zh)	2010-07-23
IL225694A (en)	2016-08-31
CA2682584A1 (en)	2008-10-16
US8546602B2 (en)	2013-10-01
TW200906829A (en)	2009-02-16
TW201431830A (zh)	2014-08-16
US20110166344A1 (en)	2011-07-07
TWI427079B (zh)	2014-02-21
EP2129224B1 (en)	2016-03-30
IL225694A0 (en)	2013-06-27
US20120302744A1 (en)	2012-11-29
AU2008237364A1 (en)	2008-10-16
US20120130068A1 (en)	2012-05-24

Publication	Publication Date	Title
BRPI0809685A2 (pt)	2016-09-27	compostos, composição farmaceuticamente aceitável e métodos de inibição da replicação do vírus da hepatite c e de tratamento ou prevenção da infecção do vírus da hepatite c em mamífero necessitado do mesmo
DK2155758T3 (da)	2012-11-05	Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
BRPI1013394A2 (pt)	2016-06-21	"composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c."
BRPI0615157A2 (pt)	2016-09-13	composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto
BRPI0820183A2 (pt)	2015-06-23	Prevenção e tratamento de infecções secundárias após infecção viral
BRPI0716483A2 (pt)	2016-06-07	inibidores do vírus da hepatite c
BR112013030045A2 (pt)	2017-11-07	composto da fórmula d-m-d ou um sal farmacêuticamente aceitável do mesmo; composto ou sal; composição farmacêutica; e método de tratamento de infecção por hepatite c em um paciente
EP2408449A4 (en)	2012-08-08	METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS
EA201301158A1 (ru)	2014-07-30	Противовирусные соединения
BRPI1010506A2 (pt)	2016-07-26	"inibidores do vírus da hepatite c"
BRPI0717737A2 (pt)	2013-10-22	Métodos para desativar vírus, reduzir o risco de infecção viral e/ou tratar enfermidades virais em um mamífero, reduzir a inflamação e risco de inflamação em um mamífero, higienizar a pele de mamíferos, manufaturar um esfregão, tratar uma superfície visada e manufaturar uma toalha de secagem antimicrobiana
ZA201001391B (en)	2010-11-24	Tetracyclic indole derivatives and their use for treating or preventing viral infections
BRPI1009324A2 (pt)	2015-11-24	compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
BRPI0907162A2 (pt)	2015-07-07	Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero
BRPI0812738A2 (pt)	2014-09-30	Composto, sal farmceuticamente aceitável, composição farmacêutica, uso de um composto, e, método par ao tratamento de uma infecção viral em um humano
BR112013020425A2 (pt)	2017-06-13	composições e métodos para o tratamento ou prevenção de infecção por vírus da hepatite b
NO20070988L (no)	2007-05-04	Vaksine for forebygging og behandling av HIV-infeksjon
IL212984A (en)	2016-12-29	Vaccines to treat or reduce the risk of mammalian viral infection containing at least two differentiated optimized HIV-1 viral polypeptides and drugs containing them
MX2010002317A (es)	2010-03-22	Derivados de indol sustituidos y metodos para su utilizacion.
HRP20160764T1 (hr)	2016-08-12	Pseudovirusi papilomavirusa za otkrivanje i liječenje tumora
EP2720716A4 (en)	2015-03-11	HEALTH BASED COMPOSITIONS AND METHOD FOR TREATING OR PREVENTING DELTA HEPATITIS VIRUS INFECTION
IL190478A0 (en)	2008-11-03	Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
EP2483273A4 (en)	2013-05-01	NEW MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
DK2646043T3 (da)	2017-05-22	Hidtil ukendte cyclosporinderivater til behandling og forebyggelse af en virusinfektion
BRPI0905388A2 (pt)	2015-10-13	"composição farmacêutica; compostos e métodos de tratamento de infecção por arenavirus"

Legal Events

Date	Code	Title	Description
2016-10-04	B15I	Others concerning applications: loss of priority	Free format text: PERDA DA PRIORIDADE US 60/907,478 DE 03/04/2007 REIVINDICADA NO PCT/US2008/059164, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O E 7O. ESTA PERDA SE DEU PELO FATO DA CESSAO PARA A PRIORIDADE REQUERIDA US 60/907,478 DE 03/04/2007, TER SIDO APRESENTADA APENAS EM 19/07/2010, SENDO QUE A ENTRADA NA FASE NACIONAL OCORREU EM 29/09/2009, OU SEJA, APOS O PRAZO REGULAR DE 60 DIAS.
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2020-06-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2020-11-17	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-12-01	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-03-09	B06G	Technical and formal requirements: other requirements [chapter 6.7 patent gazette]	Free format text: PARA QUE A PETICAO NO 870160072516 DE 02/12/2016 POSSA SER ACATADA COMO RECURSO CONTRA PERDA DE PRIORIDADE, O DEPOSITANTE DEVERA REALIZAR O PAGAMENTO DO VALOR DA RETRIBUICAO DEVIDA.(6.7)
2021-03-23	B15K	Others concerning applications: alteration of classification	Free format text: A CLASSIFICACAO ANTERIOR ERA: A01N 43/66 Ipc: C07D 417/04 (2006.01), A61K 31/5415 (2006.01), A61
2021-06-22	B12F	Other appeals [chapter 12.6 patent gazette]	Free format text: RECURSO: 870160072516 - 02/12/2016
2022-09-13	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2022-12-27	B09B	Patent application refused [chapter 9.2 patent gazette]
2025-03-11	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.